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Gabriel Maluenda, Michael A Gaglia, Manuel A Gonzalez, Israel M Barbash,
Zhenyi Xue, William O Suddath, Lowell F Satler, Kenneth M Kent, Augusto D
Pichard, Ron Waksman
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Background: Prasugrel is associated with lower rates of ischemic events and higher
major bleeding rates when compared to clopidogrel in patients with acute coronary
syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In the pivotal
trial TIMI 38, heparin was used as the primary anticoagulant, however, bivalirudin has
demonstrated lower bleeding rates when compared to heparin in such a population.
We aimed to compare the ischemic and bleeding events in patients undergoing PCI
with prasugrel and bivalirudin vs. clopidogrel and bivalirudin.
Methods: 820 patients with ACS who were subjected to PCI and stent implantation
all treated with bivalirudin were included. Of these, 79 patients (9.6%) underwent PCI
under prasugrel, and 741 with clopidogrel. The two groups were compared for bleeding
and adverse events during hospitalization, and at 30 days.
Results: Patients on clopidogrel were sicker with higher rates of hypertension (90.1%
vs. 79.7%, p=0.005), CRI (22.5% vs. 8.9%, p=0.005), history of previous MI(28.1%
vs. 15.2%, p=0.01), CABG (23.9% vs. 10.1%, p=0.005), PCI (41.8% vs. 19.0, p<0.001)
and PVD (16.9% vs. 5.1%, p=0.006). Patients on prasugrel were more often male
(77.2% vs.63.0%, p=0.01) and had more lesions in the LAD (45.0% vs. 34.5%,
p=0.04). No statistical differences were found between the groups for in-hospital and
30-day follow-up clinical outcomes. In-hospital bleeding was also similar in both
groups.
Conclusion: The present study supports the safety and the efficacy profile of prasugrel
as the antiplatelet therapy of choice when used in patients with ACS who are
undergoing PCI with bivalirudin. This combination demonstrates comparable and
acceptable rates of bleeding between prasugrel and clopidogrel without differences in
ischemic event, however, further investigations are needed to elucidate the optimal
anticoagulation regimen during PCI.
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Background: Although CYP2C19 loss-of-function (LoF) variant polymorphism is
associated with reduced response to clopidogrel, it is not determined whether two most
common variants (*2 and *3) have similar pharmacodynamic influences on the additive
platelet inhibition by alternative increasing clopidogrel dosage (150 mg/d). We
performed this study to determine additive effect of double-dose clopidogrel (150
mg/d) in high-risk patients undergoing PCI according to the status of CYP2C19*2 vs.
*3 variant carriage.
Methods: High-risk patients undergoing PCI (n=126) were enrolled. Platelet reactivity
was assessed with light transmittance aggregometry (LTA) and the VerifyNow P2Y12
assay at periprocedure and after double-dose clopidogrel therapy (≥ 1 month).
CYP2C19 genotyping was performed for the *2, *3, and *17 variants. High on-
treatment platelet reactivity (HPR) was defined as P2Y12 reaction unit > 235.
Results: Carriage of CYP2C19 LoF variant allele was 63.5% of total (n = 80): 35.7%
of *1/*2, 11.9% of *1/*3, 10.3% of *2/*2, and 5.6% of *2/*3. Although baseline
platelet measures changed proportionally according to the number of CYP2C19 variant
alleles (ANOVA tests: 0.025≤ P ≤0.315), this trend was more prominent in platelet
measures during double-dose clopidogrel administration (P <0.001 for all measures).
Additive platelet inhibition by alternative clopidogrel dosage was inversely associated
with the number of CYP2C19 LoF variant allele. When we compared the
pharmacodynamic influence of LoF variant allele carriage, there were no significant
differences in platelet measures and the prevalence of HPR between carriers of
CYP2C19*2 and/or *3 allele irrespective of the number of LoF variant allele.
Conclusion: Alternative usage of double-dose clopidogrel increases the magnitude of
platelet inhibition according to the number of CYP2C19 LoF variant allele.
CYP2C19*3 variant carriage diminishes pharmacodynamic effect of double-dose
clopidogrel, which may be as potent as the effect of CYP2C19*2 allele.
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Cytochrome P450 2C19 Loss-Of-Function Genetic Variants but not
Paraoxonase-1 Activity Modulate P2Y12 Blockade in Response to Clopidogrel
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Background: There is wide interindividual variability in the efficiency of clopidogrel
active metabolite formation, partly due to genetic factors, and this influences risk of
ischaemic events in clopidogrel-treated patients. Recent data have suggested that
paraoxonase-1 (PON1) activity, predominantly determined by Q192R genotype,
influences clopidogrel active metabolite formation. We studied the early and late effects
of CYP2C19 loss-of-function (LOF) variants and PON1 activity on P2Y12 receptor
blockade in clopidogrel-treated acute coronary syndrome (ACS) patients.
Methods: Patients with non-ST elevation ACS and STEMI undergoing primary PCI
were studied after receiving 300-600mg loading dose and 75 mg daily of clopidogrel.
Blood samples were obtained during hospitalisation and after at least 30 days
maintenance therapy. Platelet reactivity was assessed using light transmittance
aggregometry (LTA, ADP 5 and 20 uM), and VASP phosphorylation assay. Unblocked
P2Y12 receptor number was estimated using 33P-2MeSADP binding assay.
Genotyping was performed for CYP2C19*2-8 and PON1 Q192R. Plasma PON1
activity was determined using paraoxon assay. Data are mean ± SD.
Results: 88 patients (72 NSTE ACS, 16 STEMI) were studied during hospitalization
and 69 (56 NSTE ACS, 13 STEMI) during maintenance therapy. During
hospitalization, CYP2C19 LOF variants compared to wild-type were associated with
higher platelet reactivity (LTA, ADP 5 uM final extent 27 ± 17% vs 16 ± 25%, p =
0.03; VASP PRI 73 ± 15% vs 61 ± 22%, p = 0.02) and unblocked P2Y12 receptor
number (101 ± 116 vs 58 ± 58/platelet, p = 0.03) while neither PON1 Q192R genotype
or PON1 activity, which were closely associated with each other, were associated with
any difference in these parameters. Similar patterns were seen during follow-up.
Conclusion: Genetically-determined PON1 activity does not appear to modulate the
level of P2Y12 receptor blockade achieved by clopidogrel therapy in ACS patients in
contrast to genetically-predicted CYP2C19 activity either soon after loading or during
long-term maintenance therapy.
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